文献速递临床试验与 GCP

在拉各斯州开展的磷酸氯喹、硫酸羟氯喹和洛匹那韦/利托那韦治疗COVID-19疗效与安全性的多中心、随机、双盲、安慰剂对照临床试验:随机对照试验研究方案

A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-12-04

本研究为多中心、随机、双盲、安慰剂对照优效性试验,评估在标准治疗基础上加用磷酸氯喹、硫酸羟氯喹或洛匹那韦/利托那韦与仅标准治疗相比在COVID-19患者中的疗效。主要结局为第15天采用7点序数量表测量的临床状态。若任一干预药物比标准治疗更有效,拉各斯州卫生部将制定循证指南。

要点

  • 多中心、随机、双盲、安慰剂对照优效性试验,评估三种药物加标准治疗对比仅标准治疗。
  • 主要结局为第15天7点序数量表临床状态,采用意向性治疗分析。
  • 若任一干预药物更有效,拉各斯州卫生部将制定循证指南。

核心结论

  • 本研究对拉各斯州具有战略重要性,可能遏制COVID-19的健康、社会和经济负担。
  • 若三种干预药物中任一比单独标准治疗更有效,拉各斯州卫生部将制定循证指南。
  • 研究结果将在全国及各州分享,可能促成尼日利亚COVID-19治疗的标准化国家指南。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照优效性试验。
  • 研究对象为COVID-19患者,比较在标准治疗基础上加用磷酸氯喹、硫酸羟氯喹或洛匹那韦/利托那韦与仅标准治疗。
  • 主要结局为第15天采用7点序数量表测量的临床状态。
  • 研究参与者和临床医生对分配干预设盲,结局由临床医生直接评估。
  • 统计分析由对研究参与者身份和分组设盲的团队完成,采用意向性治疗分析,使用R软件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first identified in Wuhan, Hubei, China, in December 2019. It was recognized as a pandemic by the World Health Organization on 11 March 2020. Outbreak forecasting and mathematical modelling suggest that these numbers will continue to rise. Early identification of effective remedies that can shorten the duration and severity of illness is critical for Lagos State, which is the epi-centre of the disease in Nigeria. METHODS: This is a multi-centre, randomized, double-blind placebo-controlled superiority trial. The study investigates the efficacy of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir added on to standard of care compared to standard of care only in patients with COVID-19 disease. The primary outcome is the clinical status of patients measured using a 7-point ordinal scale at day 15. Research participants and clinicians will be blinded to the allocated intervention. Outcome measures will be directly assessed by clinicians. Statistical analysis will be done by a team blinded to the identity and allocation of research participants. Data analysis will follow intention-to-treat methods, using R software. DISCUSSION: The current study is of strategic importance for Lagos State in potentially curbing the health, social and economic burden of COVID-19 disease. Should the current study demonstrate that either of the three intervention drugs is more efficacious than standard therapy alone, the State Ministry of Health will develop an evidence-based guideline for the management of COVID-19 in Lagos State. The findings will also be shared nationally and with other states which may lead to a standardized national guideline for the treatment of COVID-19 in Nigeria. TRIAL REGISTRATION: Pan African Clinical Trials Register PACTR202004801273802 . Registered prospectively on April 2, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Abayomi A, Osibogun A, Ezechi O, et al. A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial. Trials. 2021. PMID: 34863267. doi:10.1186/s13063-021-05675-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。